05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
Carolyn Cross |
156,314,029 |
£19,539,254 |
Nicolas Loebel |
3,538,991 |
£442,374 |
Junaid Bajwa |
1,193,697 |
£149,212 |
Jean Duvall |
1,163,529 |
£145,441 |
Jean Charest |
353,356 |
£44,170 |
Simon Sinclair |
256,327 |
£32,041 |
Carolyn Cross |
119,258,222 |
£14,907,278 |
M&G Plc |
67,254,901 |
£8,406,863 |
hInsight-NX, LLC |
42,272,654 |
£5,284,082 |
Robert Cross |
37,772,652 |
£4,721,582 |
Albemarle Life Sciences Fund |
15,105,882 |
£1,888,235 |
CRUX Asset Management |
9,298,090 |
£1,162,261 |
Chelverton Asset Management |
7,957,311 |
£994,664 |
17:08 |
84,500 @ 12.50p |
14:52 |
33,997 @ 12.10p |
11:38 |
100,000 @ 12.60p |
11:31 |
1,044 @ 13.00p |
11:31 |
450,000 @ 13.00p |
Chair |
Jean Charest |
CEO |
Carolyn Cross |
Top of Page
You are here:
research